Supported by Cara Therapeutics
This activity is not certified for credit.
Friday, September 9
Traditional mu opioid receptor agonists play an important role in the management of acute and chronic pain. However, their use is associated with the public health epidemics of abuse, misuse, and diversion, as well mortality and morbidity due to opioid-associated overdose and respiratory depression. In addition, mu opioid receptor agonists cause other adverse effects, such as nausea and vomiting, which can delay postoperative recovery and increase healthcare costs.
A novel peripherally acting kappa opioid receptor agonist, CR845, is currently in Phase 3 trials for postoperative pain (I.V. CR845) and in Phase 2 trials for chronic pain (Oral CR845). Because of its unique pharmacologic properties, CR845 has been shown to produce significant analgesia with low abuse potential and little to no traditional mu opioid side effects, such as nausea and vomiting, pruritus, and respiratory depression.
Please join us for this PDM program, where the faculty will describe the pharmacology of CR845, present clinical data for CR845, and consider CR845’s potential place in analgesic therapy for acute and chronic pain.
After attending this PDM program, participants should be better able to:
Joseph Stauffer, DO, MBA
Michael J. Brennan, MD